Enantioselective de novo synthesis of 14-hydroxy-6-oxomorphinans
- PMID: 38787679
- PMCID: PMC11155717
- DOI: 10.1039/d4cc01788a
Enantioselective de novo synthesis of 14-hydroxy-6-oxomorphinans
Abstract
The enantioselective de novo synthesis of pharmacologically important 14-hydroxy-6-oxomorphinans is described. 4,5-Desoxynaltrexone and 4,5-desoxynaloxone were prepared using this route and their biological activities against the opioid receptors were measured.
Conflict of interest statement
There are no conflicts to declare.
Figures
Similar articles
-
Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.Bioorg Med Chem. 2016 May 15;24(10):2199-205. doi: 10.1016/j.bmc.2016.03.040. Epub 2016 Mar 25. Bioorg Med Chem. 2016. PMID: 27079125
-
Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.Bioorg Med Chem Lett. 2003 Feb 10;13(3):529-32. doi: 10.1016/s0960-894x(02)00934-4. Bioorg Med Chem Lett. 2003. PMID: 12565965
-
Reporter affinity labels: an o-phthalaldehyde derivative of beta-naltrexamine as a fluorogenic ligand for opioid receptors.J Med Chem. 2000 Jun 29;43(13):2489-92. doi: 10.1021/jm000138s. J Med Chem. 2000. PMID: 10891107 No abstract available.
-
Recent progress in research on narcotic antagonists.Prog Drug Res. 1976;20:45-100. doi: 10.1007/978-3-0348-7094-8_3. Prog Drug Res. 1976. PMID: 189354 Review. No abstract available.
-
Naldemedine: Peripherally Acting Opioid Receptor Antagonist for Treating Opioid-induced Adverse Effects.Curr Top Med Chem. 2020;20(31):2830-2842. doi: 10.2174/1568026620666200710105953. Curr Top Med Chem. 2020. PMID: 32648846 Review.
References
-
- Devereaux A. L. Mercer S. L. Cunningham C. W. ACS Chem. Neurosci. 2018;9:2395–2407. doi: 10.1021/acschemneuro.8b00150. - DOI - PubMed
- Chambers S. A. DeSousa J. M. Huseman E. D. Townsend S. D. ACS Chem. Neurosci. 2018;9:2307–2330. doi: 10.1021/acschemneuro.7b00528. - DOI - PMC - PubMed
- Olson M. E. Eubanks L. M. Janda K. D. J. Am. Chem. Soc. 2019;141:1798–1806. doi: 10.1021/jacs.8b09756. - DOI - PMC - PubMed
-
- World Health Organisation (WHO). “WHO Model List of Essential Medicines – 23rd list, 2023’’ (Publication WHO/MHP/HPS/EML/2023.02, WHO, 2023; https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02)
-
- Revesz L. Siegel R. A. Buescher H. H. H. Marko M. Maurer R. Meigel H. Helv. Chim. Acta. 1990;73:326–336. doi: 10.1002/hlca.19900730212. - DOI
- Zhang A. Li F. Ding C. Yao Q. Knapp B. I. Bidlack J. M. Neumeyer J. L. J. Med. Chem. 2007;50:2747–2751. doi: 10.1021/jm0701674. - DOI - PubMed
- Li F. Gaob L. Yin C. Chen J. Liu J. Xie X. Zhang A. Bioorg. Med. Chem. Lett. 2009;19:4603–4606. doi: 10.1016/j.bmcl.2009.06.093. - DOI - PubMed
- Li F. Yin C. Chen J. Liu J. Xie X. Zhang A. Chem. Biol. Drug Des. 2009;74:335–342. doi: 10.1111/j.1747-0285.2009.00849.x. - DOI - PubMed
-
- Yamamoto N. Fujii H. Nemoto T. Nakajima R. Momen S. Izumimoto N. Hasebe K. Mochizuki H. Nagase H. Bioorg. Med. Chem. Lett. 2011;21:4104–4107. doi: 10.1016/j.bmcl.2011.04.147. - DOI - PubMed
- Osa Y. Ida Y. Fujii H. Nemoto T. Hasebe K. Momen S. Mochizuki H. Nagase H. Chem. Pharm. Bull. 2007;55:1489–1493. doi: 10.1248/cpb.55.1489. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources